Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

HER2

25th Feb 2026

Plain language summary: DESTINY-Lung02 study of trastuzumab deruxtecan for HER2-mutant metastatic non-small-cell lung cancer

23rd Sep 2024

Plain language summary of zolbetuximab with chemotherapy for advanced inoperable or metastatic stomach and gastroesophageal junction cancers

28th Aug 2024

DESTINY-Lung01 Study: a plain language summary on Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer

This is a summary of an article describing an ongoing study called MOUNTAINEER. This article was published in The Lancet Oncology in 2023. The study included 117 adults with metastatic HER2-positive colorectal cancer. The researchers wanted to know whether a combination of 2 drugs called tucatinib and trastuzumab could shrink the participants’ cancer. The researchers also wanted to know whether receiving tucatinib alone could also shrink the participants’ cancer
18th Jan 2024

The MOUNTAINEER study: a plain language summary looking at how effective and safe tucatinib plus trastuzumab is for treating people with metastatic colorectal cancer

his article summarizes the results of a study called monarcHER. The study included participants with a certain type of aggressive breast cancer called HR+, HER2+ advanced breast cancer (ABC) that had their disease worsen or return after multiple previous therapies. This summary intends to help you understand the impact of a non-chemotherapy treatment called abemaciclib in people with HR+, HER2+ ABC. When the study was planned, HER2-targeted therapy (i.e., trastuzumab) was standard treatment and was typically combined with chemotherapy and endocrine therapy (i.e., fulvestrant). However drug resistance can develop when HER2+ targeted therapy is used for a long time, making it less effective and allowing cancer to grow or spread to other parts of the body. When this happens, few chemotherapy-free options are available. Because of the chemotherapy side effects, this is not desirable. There is an urgent need to develop new, effective, safe and tolerable treatment options for patients with HR+, HER2+ ABC. The monarcHER study compared the effects of abemaciclib plus trastuzumab with or without fulvestrant to the standard of care treatment.
6th Oct 2023

A plain language summary of the monarcHER study: abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy